Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Desmosomes01:05

Desmosomes

The term desmosome derives from the Greek words "desmo" and "soma" meaning "adhesion bodies." This structure was first observed during the late 1800s and described as small, dense nodules in the epidermis. Desmosomes are button-like structures that help form an interlinked network of intermediate filaments across the cells. These junctions are  essential to hold cells together under mechanical stress and to maintain tissue integrity. Desmosomes are multi-protein complexes comprising desmosomal...
Diphtheria01:28

Diphtheria

Diphtheria is an acute, toxin-mediated infectious disease that primarily affects the upper respiratory tract. It is caused by Corynebacterium diphtheriae, a Gram-positive, pleomorphic rod that lacks spore-forming capability and exhibits a characteristic club-shaped morphology under microscopic examination. While C. diphtheriae can asymptomatically colonize mucosal surfaces, clinical disease manifests only when the bacterial strain is lysogenized by a specific β-corynephage. This phage...
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comment on 'Incidence and Mortality of Mucous Membrane Pemphigoid in France': reply from authors.

The British journal of dermatology·2026
Same author

Correction: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.

American journal of clinical dermatology·2026
Same author

Daratumumab as a therapeutic option for rituximab-recalcitrant pemphigus.

The Journal of investigative dermatology·2026
Same author

Tocilizumab for severe and refractory mucous membrane pemphigoid.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Incidence and Mortality of Mucous Membrane Pemphigoid in France.

The British journal of dermatology·2026
Same author

Baricitinib and low-dose prednisone for very severe alopecia areata: A retrospective case series.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same journal

Artificial Intelligence in medical research and publishing: progress, risks, and future perspectives.

Presse medicale (Paris, France : 1983)·2026
Same journal

Ethical, legal, and regulatory challenges in AI-based healthcare tools.

Presse medicale (Paris, France : 1983)·2026
Same journal

Decision-making for clinicians.

Presse medicale (Paris, France : 1983)·2026
Same journal

Beyond one-size-fits-all: Personalising health communication to drive real behaviour change.

Presse medicale (Paris, France : 1983)·2026
Same journal

Metacognition and post-decisional processing in clinical decision-making.

Presse medicale (Paris, France : 1983)·2026
Same journal

Fast-and-frugal decision trees for clinicians.

Presse medicale (Paris, France : 1983)·2026
See all related articles

Related Experiment Video

Updated: Jun 9, 2026

Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

[Pemphigus].

Hélène Lapeyre-Liénard1, Pascal Joly

  • 1Hôpital Charles-Nicolle, clinique dermatologique, Inserm U 905, centre de référence maladies bulleuses autoimmunes, 76031 Rouen cedex, France.

Presse Medicale (Paris, France : 1983)
|September 7, 2010
PubMed
Summary
This summary is machine-generated.

Pemphigus is a rare autoimmune blistering disease affecting skin and mucous membranes. Diagnosis involves clinical, histological, and serological tests, with treatments including corticosteroids, immunosuppressants, IVIg, or rituximab.

More Related Videos

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid
05:05

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid

Published on: June 17, 2025

Related Experiment Videos

Last Updated: Jun 9, 2026

Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid
05:05

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid

Published on: June 17, 2025

Area of Science:

  • Autoimmune diseases
  • Dermatology
  • Immunology

Context:

  • Pemphigus is a rare autoimmune blistering disorder.
  • It affects the skin and mucous membranes.
  • Three main types exist: pemphigus vulgaris, pemphigus foliaceus, and paraneoplastic pemphigus.

Purpose:

  • To outline the diagnostic methods for pemphigus.
  • To describe current treatment strategies for pemphigus.

Summary:

  • Diagnosis relies on clinical presentation, histology, direct immunofluorescence, and serological assays like indirect immunofluorescence, immunoblot, and ELISA.
  • Treatment typically involves oral corticosteroids, often combined with immunosuppressants.
  • Refractory cases or those with contraindications may receive intravenous immunoglobulins or rituximab (anti-CD20 antibody).

Impact:

  • Improved understanding of pemphigus diagnosis and management.
  • Highlights the role of immunotherapies in pemphigus treatment.
  • Provides a concise overview for clinicians and researchers in dermatology and immunology.